Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.

Revenue
−7.01%
EPS
−101.0%
Free cash flow
+561.9%
Total debt
−90.1%

Quarter to September 2026, against a year earlier

86.56 2.79 −3.12%
Market cap
$14.8B
P/E
97.3×
Fwd P/E
47.7×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a

Solventum Corporation (SOLV) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
MedSurg 4,817 57.86%
Health Information Systems 1,360 16.34%
Dental Solutions 1,349 16.20%
Purification and Filtration Segment 497 5.97%
Other, not broken out 302 3.63%
Gross margin 53.47%
Operating margin 26.20%
Pre-tax margin 20.58%

Revenue by product or service $m

Line FY2025 FY2024 FY2023 FY2022
Cost of product 6,349 6,348 6,296 6,300
Cost of software and rentals 1,976 1,906 1,901 1,830
Revenue 8,325 8,254 8,197 8,130

Gross profit by product or service $m, and margin

Revenue by segment $m

Line FY2025 FY2024 FY2023 FY2022
MedSurg 4,817 4,637 4,632 4,585
Health Information Systems 1,360 1,306 1,285 1,227
Dental Solutions 1,349 1,295 1,329 1,327
Purification and Filtration Segment 497 709 689 991
Other, not broken out 302 307 262 —
Revenue 8,325 8,254 8,197 8,130

Operating income by segment $m, and margin

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022
United States 4,668 4,559 4,471 4,450
International 3,657 3,695 3,726 3,680
Revenue 8,325 8,254 8,197 8,130

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.